# A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants

> **NCT06901336** · PHASE1 · COMPLETED · sponsor: **Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]-STX-478

## Key facts

- **NCT ID:** NCT06901336
- **Lead sponsor:** Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-20
- **Primary completion:** 2025-05-06
- **Final completion:** 2025-05-06
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06901336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06901336, "A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06901336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*